Frost & Sullivan updates study U.S. Inflammatory Disease Drug Delivery - Patient Perspective, which investigates physician and customer preferences and prescribing trends relative to drug delivery considerations for specific diseases - rheumatoid arthritis, Crohn's disease and psoriasis.
"With the exception of psoriasis, a majority of patients take oral medication for an inflammatory condition," states Jennifer Brice, industry manager for Frost & Sullivan. "Most patients are satisfied with taking an oral drug versus an injection or topical gel/cream. Oral drug delivery is most associated with ease of self-administration, the dominant consideration for selecting drug delivery types, as well as convenience and low cost."
If you are interested in more information on this study, please send an email to Johanna Haynes, Corporate Communications, at johanna.haynes[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.
U.S. Inflammatory Disease Drug Delivery - Patient Perspective is a re-analysis of a 2008 study. This information encompasses feedback provided by U.S. patients on aspects of drug delivery for inflammatory diseases consisting of rheumatoid arthritis, Crohn's disease and psoriasis, enabling interested stakeholders to gain insight into current and future trends. Frost & Sullivan conducted a web-based survey of 110 U.S. inflammatory disease patients in Q4 2007 - January 2008.
Research Objectives are as follows:
• Identify drug delivery trends within specific disease areas;
• Determine product attributes relative to delivery that are considered important by patients;
• Identify prospective patient preferences and willingness to try new technologies as well as determine key drivers of adoption/non-adoption.
Respondents were asked about general awareness of drug delivery types, availability and usage, frequency of usage, satisfaction and reasons for satisfaction with method used, willingness and reasons for willingness to use, barriers for usage, and reasons for preference.
Although each drug delivery method is associated with unique benefits such as minimal or no discomfort and rapid onset of drug action, the future of drug delivery for inflammatory diseases is in the oral therapeutic market.
"Seventy-five percent of patients that use oral drug delivery for their psoriasis treatment are very satisfied/ satisfied versus only 55% of topical gel/cream users being very satisfied/ satisfied," observes Brice. "Reasons for satisfaction with the oral drug delivery method are easy to self administer (reported by 60% of patients), low cost (reported by 20% of patients) and convenience (reported by 20% of patients). Sixty-six percent of Crohn's disease patients and 91% of rheumatoid arthritis patients noted they are very satisfied/ satisfied with oral delivery use in their treatment."
This Frost & Sullivan research service entitled U.S. Inflammatory Disease Drug Delivery - Patient Perspective provides insight into ophthalmologists views on patient compliance with medication instructions, their considerations in selecting medications, and their opinions of various brands of medication. In this research, Frost & Sullivan's expert analysts thoroughly examine the following: patient compliance with eye care medication instructions, factors impacting prescriptions for eye care medications, and preferences for eye disease medications, including glaucoma medications in particular.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.
U.S. Inflammatory Disease Drug Delivery - Patient Perspective / N835-52